ArticleBMC medicine2025
Two structural alteration patterns of the thalamus in patients with schizophrenia.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe thalamus has been reported as structurally impaired in individuals with schizophrenia. Previous studies have demonstrated structural heterogeneity within the thalamus in schizophrenia. However, the alteration patterns among patient subtypes defined by thalamic nuclei remain unclear.
methodsThis study included 124 drug-naïve individuals with first-episode schizophrenia (FES) as the discovery cohort for thalamic subtype identification. Volumes of thalamic nuclei were used as inputs for k-means + + cluster analysis to identify patient subtypes. Subsequently, a machine learning classifier was developed in the discovery cohort, and was validated in an independent cohort with FES (N = 68), and applied in two cohorts with long-term schizophrenia, containing 95 treated individuals with long-term illness and 30 never-treated individuals with long-term illness, respectively. Additionally, the respective groups of controls were recruited as normative references for cognitive and brain structural characteristics.
resultsWe identified two highly replicable thalamic subtypes in individuals with FES: one with widespread volumetric reductions (subtype 1) and another with widespread volumetric increases (subtype 2). A classifier trained on this distinction validated the subtypes in an independent FES cohort. In long-term illness, the reduced-volume pattern of subtype 1 was consistent but more severe, with treated patients exhibiting greater volumetric deficits and cognitive abnormalities than their FES counterparts. Conversely, the increased-volume pattern of subtype 2 was attenuated in long-term illness, manifesting as selected increases in certain nuclei in treated patients and showing no significant alterations in never-treated patients.
conclusionsOur findings demonstrate two neuroanatomical thalamic subtypes in schizophrenia. Subtype 1, characterized by severe and progressive thalamocortical deficits, represents a critical subgroup that may benefit from early detection and cognitive-focused interventions. The attenuation of subtype 2 in chronic illness suggests its pathophysiology may be distinct and associated with treatment or disease course. Future longitudinal studies tracking thalamic heterogeneity from the first-episode drug-naïve stage are essential to clarify the progression of these subtypes and their impact on cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.